nocompromised Patients Proof
Selected Abstract
Coley Pharmaceutical Group's CpG 7909 Active in Immunocompromised Patients; - Proof-of-Concept Clinical Study Demonstrates Ability of CpGs to Rapidly Generate Response in Debilitated Immune Systems -.
WELLESLEY, Mass., and OTTAWA -- WELLESLEY, Mass., and OTTAWA, Feb. 13 /PRNewswire/ -- Coley Pharmaceutical Group, Inc. today announced preliminary results from a physician-sponsored human clinical study. Results from the proof-of-principle study demonstrate that Coley's CpG 7909, when used in ... February 13, 2003; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
